Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Immunization with GTU-MultiHIV B and LIPO-5 in HIV-1
NCT01492985Phase 2Completed
- Sponsor
- ANRS
- Start
- Jul 2013
- Primary completion
- Oct 2016
- Modality
- Prophylactic Vaccines, Peptides, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GTU-MultiHIV B clade vaccine and LIPO-5 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ANRS. Primary endpoint: Plasma HIV-1 RNA level at 48 weeks. Started Jul 2013; status: completed.
02
Drugs
GTU-MultiHIV B clade vaccineLIPO-5
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01492985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01492985.